{"id":"NCT02059187","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)","officialTitle":"A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-11","primaryCompletion":"2015-03-11","completion":"2015-03-11","firstPosted":"2014-02-11","resultsPosted":"2017-03-08","lastUpdate":"2018-09-06"},"enrollment":531,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"MK-1293","otherNames":[]},{"type":"DRUG","name":"Lantus™","otherNames":["Insulin glargine [rDNA origin]"]},{"type":"DRUG","name":"Prandial insulin","otherNames":[]}],"arms":[{"label":"MK-1293","type":"EXPERIMENTAL"},{"label":"Lantus™","type":"ACTIVE_COMPARATOR"}],"summary":"This 24-week study is a safety and efficacy comparison of MK-1293 and Lantus™ in participants with type 2 diabetes mellitus (T2DM). The primary hypothesis is that after 24 weeks, the mean change in hemoglobin A1c (A1C) from baseline is non-inferior (with margin of 0.4%) in participants treated with MK-1293 compared with that in participants treated with Lantus™.","primaryOutcome":{"measure":"Change From Baseline in Participant Hemoglobin A1C Level at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"MK-1293","deltaMin":-1.28,"sd":null},{"arm":"Lantus™","deltaMin":-1.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":30},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["29761615"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":263},"commonTop":["Hypoglycaemia","Upper respiratory tract infection"]}}